Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company employs 12 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
RGC stock price ended at $29.02 on 木曜日, after rising 8.61%
On the latest trading day Feb 12, 2026, the stock price of RGC rose by 8.61%, climbing from $26.92 to $29.02. During the session, the stock saw a volatility of 17.56%, with prices oscillating between a daily low of $25.85 and a high of $30.39. Notably, trading volume dropped by 136.6K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 193.1K shares were traded, equating to a market value of approximately $14.3B.